SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

OBJECTIVES: SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI. METHODS: Hamsters were infected with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Abdul, Thommes, Pia, Payne, Lloyd, Warn, Peter, Vickers, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498292/
https://www.ncbi.nlm.nih.gov/pubmed/25652749
http://dx.doi.org/10.1093/jac/dkv005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498292/
https://www.ncbi.nlm.nih.gov/pubmed/25652749
http://dx.doi.org/10.1093/jac/dkv005

Ejemplares similares